In 2015/16, five startups in this space — Stemcentrx, Gritstone Oncology, Hengrui Therapeutics, and Zai Lab secured big ticket funding rounds of $100 million and above.

2. Immuno-Oncology Report, September 2016
Tracxn
World’s Largest Startup Research Platform
2

3. Immuno-Oncology Report, September 20163
Contents
Topic Page No.
Scope of Report 05
Entrepreneur Activity 07
Investment Trend 09
Who is Investing 17
Exit Outlook - IPO, Acquisitions 21
Sub Sector Analysis 24
Interesting Companies 42
Company List 49
Team 154

4. Immuno-Oncology Report, September 20164
Illustrative Sectors We Track
ENTERPRISE
INFRASTRUCTURE
TECH
SECURITY
STORAGE
NETWORKING
MOBILITY
IT OPS
CLOUD INFRASTRUCTURE
API MANAGEMENT
BIGDATA INFRASTRUCTURE
INTERNET OF THINGS
3D PRINTING
HEALTH
EDUCATION
BIOPHARMA
DIAGNOSTICS
MEDICAL DEVICES
HEALTHCARE ANALYTICS
FITNESS AND WELLNESS
HEALTH IT
CONSUMER HEALTHTECH
MOBILE HEALTH
EDUCATION IT
SELF LEARNING
ENTERPRISE
APPLICATIONS
MOBILE
SAAS
MOBILE-FIRST ENT. APPS
INTELLIGENT ENT. APPS
OPEN SOURCE
RETAIL TECH
MARKETING TECH
STEALTH MODE
VERTICAL SAAS
MOBILE COMMERCE
MOBILE PAYMENTS
CONSUMER
FINTECH
MARKETPLACES
SUBSCRIPTION COMM.
UBER FOR X
INTERNET FIRST BRANDS
FOOD TECH
GROCERY TECH
TRAVEL
GAMING
BITCOIN
PAYMENTS

5. Immuno-Oncology Report, September 20165
Sector Overview
Scope of report
The report contains companies which are developing therapeutics to suppress or activate immune system for the treatment of
cancer. This includes all the companies which are developing antibodies, small molecules, vaccines, viral and adoptive cell
therapies for cancer. The report excludes big pharma companies, contract services providers and platform companies.
For funding, this report only includes venture capital/ private equity funding rounds and excludes debt financing and
grants/prize money.
The scope of this report includes equity as well as debt funding received by the companies.
5

6. Immuno-Oncology Report, September 2016
Scope of Report
Entrepreneur Activity
Investment Trend
Who is Investing
Exit Outlook - IPO, Acquisitions
Sub Sector Analysis
Interesting Companies
Company List
Team
6

7. Immuno-Oncology Report, September 2016
25
20
24
27
22
37
8
0
8
16
24
32
40
2010 2011 2012 2013 2014 2015 2016
NumberofCompanies
7
YoY – Number of companies founded
BeiGene Panacela Labs ADC Therapeutics Juno Therapeutics Corvus Pharmaceuticals Gritstone Oncology Hengrui Therapeutics
PsiOxus Therapeutics TG Therapeutics Armo BioSciences Jounce Therapeutics Unum Therapeutics Autolus Cell Design Labs

8. Immuno-Oncology Report, September 2016
Scope of Report
Entrepreneur Activity
Investment Trend
Who is Investing
Exit Outlook - IPO, Acquisitions
Sub Sector Analysis
Interesting Companies
Company List
Team
8
8

9. Immuno-Oncology Report, September 20169
YoY – Number of Rounds and Total Funding
Note: The funding includes debt rounds also.
$0.5B
$0.7B
$1.2B
$0.7B $0.7B
$1.6B
$2.2B
$4.1B
$1.7B
25
72
101
74 73
100
133
129
79
0
28
56
84
112
140
0.0
0.9
1.8
2.7
3.6
4.5
2008 2009 2010 2011 2012 2013 2014 2015 2016
NumberofRounds
FundingAmount(inBillions)
Funding Amount Number of Rounds

10. Immuno-Oncology Report, September 201610
YoY – Number of Rounds by Stage

11. Immuno-Oncology Report, September 201611
YoY – Funding by Stage

12. Immuno-Oncology Report, September 201612
Average Ticket Size – Early Stage

13. Immuno-Oncology Report, September 201613
Top investments in last one year

14. Immuno-Oncology Report, September 201614
Top investments in last one year

15. Immuno-Oncology Report, September 201615
Funnel view of Sector

16. Immuno-Oncology Report, September 2016
Scope of Report
Entrepreneur Activity
Investment Trend
Who is Investing
Exit Outlook - IPO, Acquisitions
Sub Sector Analysis
Interesting Companies
Company List
Team
6
16

17. Immuno-Oncology Report, September 201617
Most Active Investors in Sector
29
21
20 20
15
14 14 14
13
12
0
7
14
21
28
35
Orbimed MPM Capital Alta Partners Novo A/S Novartis
Venture Fund
5AM Ventures KPCB Versant Ventures SV
Life Sciences
Sofinnova
Ventures
TotalNumberofRounds
Alpine Immune
Sciences
Oncorus Allakos Corvus Pharmaceuticals Adicet Bio Ideaya Biosciences Cell Design Labs Gritstone Oncology Delenex
Checkmate
Pharmaceuticals
Armo BioSciences
Amphivena
Therapeutics
Kite Pharma Allakos IFM Therapeutics Igenica Zai Lab Nouscom NKT Therapeutics NextCure

18. Immuno-Oncology Report, September 201618
Where are Top Investors investing

19. Immuno-Oncology Report, September 201619
Top Investor by Stage of Entry

20. Immuno-Oncology Report, September 2016
Scope of Report
Entrepreneur Activity
Investment Trend
Who is Investing
Exit Outlook - IPO, Acquisitions
Sub Sector Analysis
Interesting Companies
Company List
Team
0
20

21. Immuno-Oncology Report, September 201621
Top IPOs in last three years

22. Immuno-Oncology Report, September 201622
Major Acquisitions in last one year

23. Immuno-Oncology Report, September 2016
Scope of Report
Entrepreneur Activity
Investment Trend
Who is Investing
Exit Outlook - IPO, Acquisitions
Sub Sector Analysis
Interesting Companies
Company List
Team
3
23

24. Immuno-Oncology Report, September 201624
September 2016Tracxn BlueBox : Immuno-Oncology
400+ companies in the sector, 343 funded in last 5 years, over $5.7B invested in 2015-16

25. Immuno-Oncology Report, September 201625
Top Business Models by Funding
$6.5B
$1.5B $1.5B
$1.1B
$536M $425M $264M $131M
0
1400
2800
4200
5600
7000
Antibody Adoptive Cell Therapy Vaccine Suite Oncolytic Virus Small Molecule Cytokines Others
TotalFundingAmount(inMillions)
# Cos. 174 30 95 31 28 20 7 16
Avg. Age 2005.8 2009.5 2005.7 2006.8 2007.9 2008.8 2002.9 2005.8
Stemcentrx NantKwest CureVac Immatics BioVex Syndax IRX Therapeutics Iconic Therapeutics
Symphogen Juno Therapeutics Argos Therapeutics BeiGene PsiOxus Therapeutics VentiRx Armo BioSciences Molecular Templates

26. Immuno-Oncology Report, September 2016
Antibody – Business Model Description
26

27. Immuno-Oncology Report, September 201627
Antibody – Entrepreneur Activity and Investment
Trend

28. Immuno-Oncology Report, September 201628
Antibody – Most Funded Companies

29. Immuno-Oncology Report, September 2016
Adoptive Cell Therapy – Business Model
Description
29

30. Immuno-Oncology Report, September 201630
Adoptive Cell Therapy – Entrepreneur Activity and
Investment Trend

31. Immuno-Oncology Report, September 201631
Adoptive Cell Therapy – Most Funded Companies

32. Immuno-Oncology Report, September 201632
Vaccine – Business Model Description
32

33. Immuno-Oncology Report, September 201633
Vaccine – Entrepreneur Activity and Investment
Trend

34. Immuno-Oncology Report, September 201634
Adoptive Cell Therapy – Most Funded Companies

35. Immuno-Oncology Report, September 201635
Suite – Business Model Description
35

36. Immuno-Oncology Report, September 201636
Suite – Entrepreneur Activity and Investment
Trend

37. Immuno-Oncology Report, September 201637
Suite – Most Funded Companies

38. Immuno-Oncology Report, September 201638
Oncolytic Virus – Business Model Description
38

39. Immuno-Oncology Report, September 201639
Oncolytic Virus – Entrepreneur Activity and
Investment Trend

40. Immuno-Oncology Report, September 201640
Oncolytic Virus – Most Funded Companies

41. Immuno-Oncology Report, September 2016
Scope of Report
Entrepreneur Activity
Investment Trend
Who is Investing
Exit Outlook - IPO, Acquisitions
Sub Sector Analysis
Interesting Companies
Company List
Team
41

42. Immuno-Oncology Report, September 201642
Interesting Unfunded Companies
Company Overview Business Model
immunophotonics.com
Aurora Biopharma
(2016, Miami)
CAR T cell based immunotherapies for solid cancers. Adoptive Cell Therapy > T Cell
batubiologics.com
Chestnut Pharmaceuticals
(2015, Toronto)
Developing novel therapeutics for metastatic cancers employing a comprehensive
approach to reverse the metastatic state of tumor cells.
Antibody > Tumor-targeting
affinicon.com
AR Pharma
(2015, Woburn)
Monoclonal antibody to treat B-cell chronic lymphocytic leukemia Antibody > Suite
AngioClast
(2015, Cambridge (UK))
Developing antibody drug conjugate for treatment of Glioblastoma multiforme.
Antibody > Tumor-targeting >
Antibody Drug Conjugates
GO Therapeutics
(2013, Cambridge (US))
Developing tumor-specific antibodies for cancer immunotherapy based on cancer
glycoproteome.
Antibody > Tumor-targeting
Curated list of companies by the sector analyst are defined as Interesting

43. Immuno-Oncology Report, September 201643
Interesting Seed Companies

44. Immuno-Oncology Report, September 201644
Interesting Series A Companies

45. Immuno-Oncology Report, September 201645
Interesting Series B Companies

46. Immuno-Oncology Report, September 201646
Interesting Late Stage Companies

47. Immuno-Oncology Report, September 201647
Top Funded Deadpooled Companies

48. Immuno-Oncology Report, September 2016
Scope of Report
Entrepreneur Activity
Investment Trend
Who is Investing
Exit Outlook - IPO, Acquisitions
Sub Sector Analysis
Interesting Companies
Company List
Team
4848

49. Immuno-Oncology Report, September 201649
Immuno-Oncology – Company List
COVERS THE FOLLOWING SECTORS
Small
Molecule
Cytokines Antibody Vaccine
Oncolytic
Virus
Adoptive Cell
Therapy
Others Suite

50. Immuno-Oncology Report, September 201650
Small Molecule (1/6)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Company Details Funding Investors
Immunosuppressive Pathway
Inhibitors
Syndax [Waltham, 2005]: Syndax is a late-stage biopharmaceutical company developing entinostat as a
combination therapy in multiple cancer indications with an initial focus on tumors that have shown
sensitivity to immunotherapy, including lung cancer, melanoma and triple negative breast cancer. Entinostat
(phase3, breast cancer), its lead drug candidate is an oral, small molecule that has direct effects on both
cancer cells and immune regulatory cells, potentially enhancing the body's immune response to tumors.
$158.65M
Fidelity Investments, Orbimed, Avalon
Ventures, MPM Capital, Domain
Associates, Pappas Ventures, Forward
Ventures, Tavistock Group, Jennison
Associates, Arrowpoint Partners,
RusnanoMedInvest, Delos Capital,
EcoR1, Pappas Capital
Immunosuppressive Pathway
Inhibitors
Flexus Biosciences [San Carlos, 2013]: Flexus Biosciences focuses on small-molecule cancer
immunotherapies: IDO & TDO Inhibitors (Immune Response Checkpoint Modulators) that target regulatory T
cells. The company utilizes immunology techniques to identify Agents for Reversal of Tumor
Immunosuppression (ARTIS). Flexus has a proprietary IDO/TDO discovery program which includes its IDO-
selective, IDO/TDO dual and TDO-selective compound libraries. Cancer cells use IDO and TDO pathways to
suppress the host’s immune response in order to facilitate survival, growth, invasion, and metastasis of
malignant cells. The company has been acquired by Bristol-Myers Squibb on Feb 2015 ($800M upfront and
$450M in milestone payments).
$47M
KPCB, The Column Group, Celgene,
The Column Group
Immunosuppressive Pathway
Inhibitors
Ideaya Biosciences [San Francisco, 2015]: Ideaya Biosciences is an oncology-focused company committed to
the discovery of personalized synthetic lethality medicines targeting DNA damage and repair for genetically
defined patient populations and immuno-oncology therapies targeting the tumor microenvironment.
Synthetic lethality is a phenomenon where the independent loss-of-function of two different genes have no
significant effects on cell growth and viability, but when combined results in robust cell death. It will focus
on novel synthetic lethal interactions for genetically defined patient populations, exploiting inherent tumor
susceptibilities en-route to discovery and development of small-molecule agents to treat major human
cancers. It also focusses on modulating DNA repair to augment response to immunotherapy. In addition,
drug discovery programs will target pathways known to produce an immune suppressed tumor
microenvironment, enabling tumors to escape recognition by the host immune system.
$46M
Canaan Partners, Celgene, 5AM
Ventures, Alexandria Real Estate
Equities, NIBR, WuXi Healthcare
Ventures

51. Immuno-Oncology Report, September 201651
Small Molecule (2/6)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Company Details Funding Investors
Immunosuppressive Pathway
Inhibitors
NewLink Genetics [Ames, 1999]: NewLink Genetics is discovering and developing novel immuno-oncology
product candidates using its checkpoint inhibitor platform. The company is developing IDO pathway
inhibitors for the treatment of cancer. The indoleamine 2,3-dioxygenase (IDO) pathway regulates immune
response by suppressing T-cell function and enabling local tumor immune escape. It is developing two IDO
pathway inhibitors—GDC-0919 (in partnership with Genentech) and indoximod. Indoximod is being
developed in combination with antibodies and chemotherapy for the treatment of breast cancer (Phase 2),
pancreatic cancer (Phase 2), glioblastoma (Phase 2), melanoma (Phase 2).
$24.5M
Iowa Capital Management, Ames
Economic Development Commission
Immunosuppressive Pathway
Inhibitors
Confluence Life Sciences [St. Louis, 2010]: Confluence Life Sciences (CLS) is a drug discovery and early
development company which is focusing on developing kinase inhibitors using its proprietary technology. Its
platform KINect claims to accelerate the identification of drug candidates targeting active-site cysteine-
containing kinases. The platform has a thiol-directed chemical library of protein kinase inhibitors which has
been utilized in multiple drug discovery programs. Its internal development pipeline has programs for cancer
immunotherapy and autoimmune diseases (IL-2 Inducible T-Cell Kinase (ITK) / Tyrosine-protein Kinase
inhibitors). It is also developing programs for inflammation and cancer externally in partnership with other
pharmacy companies.
$12.81M
BioGenerator, Helix Funds, Missouri
Technology, Mercury Fund, Epidarex
Capital, St Louis Arch Angels
Immunosuppressive Pathway
Inhibitors
TPP Global Development [Edinburgh, 2008]: IOmet (previously named TPP) is a UK-based preclinical-stage
drug development company focused on cancer immunotherapy and metabolism. IOmet has a
comprehensive pipeline of IDO, TDO and dual-acting IDO/TDO inhibitors and novel GLUT1 inhibitors. IOmet
is pursuing a number of other undisclosed cancer immunotherapy and cancer metabolism targets, in
addition to a GLUT9 inhibitor program for the treatment of gout. Effective January 11, 2016, IOmet Pharma
is a wholly owned subsidiary of Merck & Co., Inc.
$12.2M Scottish Enterprise
Immunosuppressive Pathway
Inhibitors
Xios Therapeutics [Boston, 2015]: Xios Therapeutics is a biotechnology company focussed on developing
small molecule therapies for cancer. It is developing drugs which are capable of preventing tumors from
evading the immune system and targets the immuno-oncology pathways and mechanisms which can be the
potential therapeutic target for cancer treatment.
$6M Sutter Hill Ventures

52. Immuno-Oncology Report, September 201652
Small Molecule (3/6)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Company Details Funding Investors
Immunosuppressive Pathway
Inhibitors
Partikula [Miami, 2013]: Partikula is focused on developing novel mitochondrial-targeted therapeutics for
oncology using its chemical engineering technologies. It is developing programs which affect the proteins
present in and around mitochondria. Its portfolio candidates include KULA 18 and KULA 19 which inhibits
pyruvate dehydrogenase kinase (PDK) and Hexokinase respectively; KULA-200, a small peptide targeted to
inhibit the anti-apoptotic protein Bcl-2; KULA-300 cancer chemotherapeutics and KULA-101, a tumor
Microenvironment Modifier (TMEM) for cancer immunotherapy. It is planning to begin clinical studies of its
lead programs in late 2016.
$5.7M 2M Companies
Immunosuppressive Pathway
Inhibitors
ImmunoMet Therapeutics [Houston, 2015]: ImmunoMet Therapeutics (a spinoff of HanAll Biopharma) is a
development-stage biotechnology company developing oncology products with a focus on cancer
metabolism and immuno-oncology. Its novel technology is designed to disrupt cancer cell growth and
enhance anti-cancer immunity and may be used in a broad range of difficult-to-treat cancers. Its lead cancer
metabolism compound, IM156, an OXPHOS inhibitor, for the treatment of glioblastoma (brain cancer) is
expected to enter Phase 1 clinical development in the second half of 2016.
$5.2M Mirae Asset
Immunosuppressive Pathway
Inhibitors
Aminex Therapeutics [Kenmore, 2009]: Aminex Therapeutics is developing cancer immunotherapies. The
company is developing a class of immunotherapies known as suppressor class modulators. Its lead candidate
reduces polyamine uptake in cancer cells, which in turn leads to reduction in the number of myeloid-
derived suppressor cells. As a result, the innate immune system can then be triggered to attack cancer cells.
Its lead candidate AMX-513 consists of two drugs, an FDA approved polyamine synthesis inhibitor (DFMO,
difluoromethylornithine) and a novel potent polyamine uptake, or transport, inhibitor (AMXT 1501).
$4M
Immunosuppressive Pathway
Inhibitors
Oncofactor [Seattle, 2011]: Oncofactor develops cancer therapeutics that disrupt signaling pathways
between tumors and the immune system. The company is developing an oncology platform to identify and
target immune modulating proteins deferentially expressed by cancer cells. The company claims that
targeting these oncofactors will reveal cancer to the host immune system and permit clearance by native
immunity.
$3.1M
OVP Venture Partners, ARCH Venture
Partners, Alexandria Real Estate
Equities, Accelerator, Washington
Research Foundation, Amgen

53. Immuno-Oncology Report, September 201653
Small Molecule (4/6)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

54. Immuno-Oncology Report, September 201654
Small Molecule (5/6)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

55. Immuno-Oncology Report, September 201655
Small Molecule (6/6)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

56. Immuno-Oncology Report, September 201656
Cytokines (1/2)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

57. Immuno-Oncology Report, September 201657
Cytokines (2/2)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

58. Immuno-Oncology Report, September 201658
Antibody (1/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

59. Immuno-Oncology Report, September 201659
Antibody (2/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

60. Immuno-Oncology Report, September 201660
Antibody (3/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

61. Immuno-Oncology Report, September 201661
Antibody (4/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

62. Immuno-Oncology Report, September 201662
Antibody (5/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

63. Immuno-Oncology Report, September 201663
Antibody (6/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

64. Immuno-Oncology Report, September 201664
Antibody (7/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

65. Immuno-Oncology Report, September 201665
Antibody (8/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

66. Immuno-Oncology Report, September 201666
Antibody (9/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

67. Immuno-Oncology Report, September 201667
Antibody (10/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

68. Immuno-Oncology Report, September 201668
Antibody (11/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

69. Immuno-Oncology Report, September 201669
Antibody (12/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

70. Immuno-Oncology Report, September 201670
Antibody (13/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

71. Immuno-Oncology Report, September 201671
Antibody (14/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

72. Immuno-Oncology Report, September 201672
Antibody (15/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

73. Immuno-Oncology Report, September 201673
Antibody (16/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

74. Immuno-Oncology Report, September 201674
Antibody (17/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

75. Immuno-Oncology Report, September 201675
Antibody (18/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

76. Immuno-Oncology Report, September 201676
Antibody (19/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

77. Immuno-Oncology Report, September 201677
Antibody (20/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

78. Immuno-Oncology Report, September 201678
Antibody (21/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

79. Immuno-Oncology Report, September 201679
Antibody (22/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

80. Immuno-Oncology Report, September 201680
Antibody (23/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

81. Immuno-Oncology Report, September 201681
Antibody (24/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

82. Immuno-Oncology Report, September 201682
Antibody (25/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

83. Immuno-Oncology Report, September 201683
Antibody (26/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

84. Immuno-Oncology Report, September 201684
Antibody (27/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

85. Immuno-Oncology Report, September 201685
Antibody (28/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

86. Immuno-Oncology Report, September 201686
Antibody (29/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

87. Immuno-Oncology Report, September 201687
Antibody (30/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

88. Immuno-Oncology Report, September 201688
Antibody (31/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

89. Immuno-Oncology Report, September 201689
Antibody (32/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

90. Immuno-Oncology Report, September 201690
Antibody (33/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

91. Immuno-Oncology Report, September 201691
Antibody (34/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

92. Immuno-Oncology Report, September 201692
Antibody (35/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

93. Immuno-Oncology Report, September 201693
Antibody (36/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

94. Immuno-Oncology Report, September 201694
Antibody (37/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

95. Immuno-Oncology Report, September 201695
Antibody (38/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

96. Immuno-Oncology Report, September 201696
Antibody (39/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

97. Immuno-Oncology Report, September 201697
Antibody (40/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

98. Immuno-Oncology Report, September 201698
Antibody (41/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

99. Immuno-Oncology Report, September 201699
Antibody (42/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

100. Immuno-Oncology Report, September 2016100
Antibody (43/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

101. Immuno-Oncology Report, September 2016101
Vaccine (1/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

102. Immuno-Oncology Report, September 2016102
Vaccine (2/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

103. Immuno-Oncology Report, September 2016103
Vaccine (3/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

104. Immuno-Oncology Report, September 2016104
Vaccine (4/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

105. Immuno-Oncology Report, September 2016105
Vaccine (5/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

106. Immuno-Oncology Report, September 2016106
Vaccine (6/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

107. Immuno-Oncology Report, September 2016107
Vaccine (7/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

108. Immuno-Oncology Report, September 2016108
Vaccine (8/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

109. Immuno-Oncology Report, September 2016109
Vaccine (9/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

110. Immuno-Oncology Report, September 2016110
Vaccine (10/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

111. Immuno-Oncology Report, September 2016111
Vaccine (11/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

112. Immuno-Oncology Report, September 2016112
Vaccine (12/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

113. Immuno-Oncology Report, September 2016113
Vaccine (13/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

114. Immuno-Oncology Report, September 2016114
Vaccine (14/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

115. Immuno-Oncology Report, September 2016115
Vaccine (15/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

116. Immuno-Oncology Report, September 2016116
Vaccine (16/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

117. Immuno-Oncology Report, September 2016117
Vaccine (17/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

118. Immuno-Oncology Report, September 2016118
Vaccine (18/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

119. Immuno-Oncology Report, September 2016119
Vaccine (19/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

120. Immuno-Oncology Report, September 2016120
Vaccine (20/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

121. Immuno-Oncology Report, September 2016121
Vaccine (21/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

122. Immuno-Oncology Report, September 2016122
Vaccine (22/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

123. Immuno-Oncology Report, September 2016123
Vaccine (23/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

124. Immuno-Oncology Report, September 2016124
Oncolytic Virus (1/7)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

125. Immuno-Oncology Report, September 2016125
Oncolytic Virus (2/7)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

126. Immuno-Oncology Report, September 2016126
Oncolytic Virus (3/7)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

127. Immuno-Oncology Report, September 2016127
Oncolytic Virus (4/7)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

128. Immuno-Oncology Report, September 2016128
Oncolytic Virus (5/7)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

129. Immuno-Oncology Report, September 2016129
Oncolytic Virus (6/7)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

130. Immuno-Oncology Report, September 2016130
Oncolytic Virus (7/7)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

131. Immuno-Oncology Report, September 2016131
Adoptive Cell Therapy (1/8)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

132. Immuno-Oncology Report, September 2016132
Adoptive Cell Therapy (2/8)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

133. Immuno-Oncology Report, September 2016133
Adoptive Cell Therapy (3/8)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

134. Immuno-Oncology Report, September 2016134
Adoptive Cell Therapy (4/8)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

135. Immuno-Oncology Report, September 2016135
Adoptive Cell Therapy (5/8)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

136. Immuno-Oncology Report, September 2016136
Adoptive Cell Therapy (6/8)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

137. Immuno-Oncology Report, September 2016137
Adoptive Cell Therapy (7/8)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

138. Immuno-Oncology Report, September 2016138
Adoptive Cell Therapy (8/8)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

139. Immuno-Oncology Report, September 2016139
Others (1/5)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

140. Immuno-Oncology Report, September 2016140
Others (2/5)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

141. Immuno-Oncology Report, September 2016141
Others (3/5)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

142. Immuno-Oncology Report, September 2016142
Others (4/5)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

143. Immuno-Oncology Report, September 2016143
Others (5/5)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

144. Immuno-Oncology Report, September 2016144
Suite (1/9)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

145. Immuno-Oncology Report, September 2016145
Suite (2/9)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

146. Immuno-Oncology Report, September 2016146
Suite (3/9)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

147. Immuno-Oncology Report, September 2016147
Suite (4/9)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

148. Immuno-Oncology Report, September 2016148
Suite (5/9)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

149. Immuno-Oncology Report, September 2016149
Suite (6/9)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

150. Immuno-Oncology Report, September 2016150
Suite (7/9)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

151. Immuno-Oncology Report, September 2016151
Suite (8/9)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

152. Immuno-Oncology Report, September 2016152
Suite (9/9)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite

153. Immuno-Oncology Report, September 2016
Scope of Report
Entrepreneur Activity
Investment Trend
Who is Investing
Exit Outlook - IPO, Acquisitions
Sub Sector Analysis
Interesting Companies
Company List
Team
153

154. Immuno-Oncology Report, September 2016154
Team
154
Shubham Garg
Analyst, BioPharma
Vikash Peesapati
Lead Analyst, Life Sciences